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S U M M A R Y
Our objective was to compare the ertapenem minimal inhibitory concentrations (MICs) for Enterobacter
cloacae isolates categorized intermediate or resistant to ertapenem when measured with the Vitek 2
system, with the MICs for these isolates when measured by two methods performed in agar medium: the
Etest and agar plate dilution method (APDM). Overall, 50 E. cloacae isolates were included in the study.
The mean MIC of ertapenem was 2.92  1.77 mg/ml according to the Vitek 2 system, 0.94  0.84 mg/ml
according to the Etest strips, and 0.93  0.62 mg/ml according to the APDM. Furthermore, the MICs
determined by the Vitek 2 system were higher than the MICs determined by the two other methods for 96% of
strains. Lastly, according to the Etest strips and APDM, 42% of E. cloacae were susceptible to ertapenem. No
carbapenemase was identiﬁed by the screening method used. Using the Vitek 2 system to determine
ertapenem MICs for E. cloacae can have potential consequences in terms of additional carbapenemase-
detecting tests and antimicrobial therapy. It would be interesting to determine if the Vitek 2 system is more
effective for the detection of carbapenemase producers with low-level carbapenem resistance than the two
methods performed in agar medium.
 2013 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. 
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Acquired carbapenemase-producing Enterobacteriaceae pose a
considerable threat to clinical patient care and public health.1
Therefore, it is important to identify them in order to implement
speciﬁc measures to prevent their dissemination. It is now
suggested that carbapenemase-detecting phenotypic tests should
be performed in isolates exhibiting even a small reduction in
susceptibility to carbapenems, including ertapenem.2
Our objective was to compare the ertapenem minimal
inhibitory concentrations (MICs) for Enterobacter cloacae when
measured with the Vitek 2 system (bioMe´rieux, France) and when
measured by methods performed in agar medium.       
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This study focused on E. cloacae strains that had been isolated in
2011 and 2012 in our hospital. All strains belonging to the
intermediate or resistant categories to ertapenem according to the
recommendations of the European Committee on Antimicrobial
Susceptibility Testing (http://www.eucast.org; 0.5 < ertapenem
MIC  1 mg/ml for the intermediate category, and ertapenem MIC
> 1 mg/ml for the resistant category) were included.
MICs had been measured routinely by the automated dilution
method with the Vitek 2 system. For the current study, the MICs
were also measured in Mueller–Hinton agar by means of gradient
diffusion testing with Etest strips for imipenem and meropenem
(Oxoid Ltd, Basingstoke, UK) and for ertapenem and doripenem
(bioMe´rieux, Marcy l’Etoile, France). Lastly, the ertapenem MICs
were determined by agar plate dilution method (APDM; with
ertapenem concentrations between 0.125 and 8 mg/ml). All agar
plates were incubated at 37 8C for 24 h. The following strains were
used for quality control (ertapenem MICs): Escherichia coli ATCC
25922, three E. cloacae isolates that had been characterized
susceptible to ertapenem by Vitek 2 system and Etest strips in ourociety for Infectious Diseases. Open access under CC BY-NC-ND license.
Table 1
Enterobacter cloacae categorized intermediate or resistant to ertapenem by Vitek 2 system: beta-lactamase screening, ertapenem MICs (mg/ml) determined by the three
different methods, and MICs of three other carbapenems determined by Etest strips
Strains Ertapenem
MIC
(Vitek 2)
Ertapenem
MIC
(E-test)
Ertapenem
MIC
(Dilution in
agar medium)
Imipenem MIC
(E-test)
Meropenem
MIC
(E-test)
Doripenem
MIC
(E-test)
ESBL
screening
Carbapenemase-detecting
phenotypic test
1 2 1 0.5 0.12 0.06 0.032 Negative Negative
2 2 0.75 0.25 0.25 0.12 0.094 Negative Negative
3 1 0.5 0.5 0.5 0.12 0.094 Positive Negative
4 4 1 1 0.5 0.12 0.094 Positive Negative
5 4 1 1 0.25 0.12 0.094 Positive Negative
6 >8 3 1 1 1 0.75 Negative Negative
7 4 2 2 0.5 0.12 0.125 Negative Negative
8 4 1.5 0.5 0.5 0.12 0.125 Positive Negative
9 1 0.25 0.125 0.25 0.03 0.032 Positive Negative
10 4 1.5 0.25 0.5 0.25 0.125 Negative Negative
11 4 3 2 0.25 0.12 0.094 Positive Negative
12 >8 1.5 0.5 0.25 0.12 0.64 Negative Negative
13 2 0.75 0.5 0.5 0.12 0.047 Positive Negative
14 2 1 0.5 0.5 0.12 0.094 Negative Negative
15 2 1.5 2 0.5 0.12 0.094 Positive Negative
16 1 0.75 0.25 0.25 0.12 0.094 Positive Negative
17 1 0.125 0.25 0.25 0.03 0.016 Negative Negative
18 2 0.25 1 0.25 0.12 0.064 Positive Negative
19 2 1 1 0.5 0.12 0.094 Negative Negative
20 4 0.75 0.25 0.25 0.03 0.023 Negative Negative
21 4 0.5 0.25 0.25 0.06 0.047 Positive Negative
22 2 0.75 1 0.25 0.06 0.064 Positive Negative
23 1 0.25 1 0.25 0.06 0.047 Negative Negative
24 2 0.38 1 0.5 0.06 0.094 Negative Negative
25 4 1.5 2 0.25 0.12 0.094 Positive Negative
26 0.75 0.75 2 0.5 0.12 0.125 Negative Negative
27 2 1 1 0.25 0.06 0.047 Positive Negative
28 4 0.38 0.5 0.25 0.12 0.032 Positive Negative
29 8 4 1 0.25 0.12 0.094 Positive Negative
30 1 0.25 0.5 0.5 0.06 0.032 Positive Negative
31 4 2 2 1.5 1 0.5 Negative Negative
32 1 3 1 0.5 0.25 0.19 Negative Negative
33 2 1 1 0.25 0.12 0.125 Negative Negative
34 4 0.25 2 0.5 0.12 0.064 Negative Negative
35 4 1 1 0.12 0.06 0.064 Positive Negative
36 1 0.75 0.25 0.12 0.03 0.016 Positive Negative
37 4 1 2 0.25 0.12 0.125 Positive Negative
38 2 0.25 0.5 0.5 0.06 0.064 Positive Negative
39 2 0.75 1 0.25 0.06 0.047 Positive Negative
40 2 0.38 2 0.5 0.12 0.094 Positive Negative
41 2 0.25 0.5 0.25 0.06 0.047 Negative Negative
42 4 0.5 0.25 0.25 0.06 0.032 Negative Negative
43 4 1 1 0.25 0.12 0.064 Negative Negative
44 4 0.5 1 0.25 0.12 0.094 Negative Negative
45 2 0.19 2 0.5 0.06 0.125 Negative Negative
46 4 0.12 0.125 0.06 0.008 0.004 Positive Negative
47 2 0.38 1 0.25 0.06 0.064 Negative Negative
48 2 0.25 1 0.25 0.06 0.047 Positive Negative
49 4 0.25 1 1 0.12 0.25 Negative Negative
50 1 0.25 0.25 0.25 0.06 0.047 Positive Negative
E. coli ATCC 25922 0.5 0.125
E. cloacae
control 1
0.5 0.25
E. cloacae
control 2
0.5 0.25
E. cloacae
control 3
0.5 0.25
OXA-48-producing E. cloacae 4 0.50
MIC, minimal inhibitory concentration; ESBL, extended-spectrum beta-lactamase.
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which the ertapenem MIC was 4 mg/ml with the Vitek 2 system
and 0.50 mg/ml with the Etest strips in our laboratory.
In addition, all strains were tested for the presence of an
extended-spectrum beta-lactamase (ESBL) by the combined disk
method (Rosco Diagnostica A/S, Taastrup, Denmark).
Phenotypic testing for carbapenemases was performed by
means of the double-disk synergy test (DDST) KPC + MBL ConﬁrmID Kit (Rosco Diagnostica A/S) using meropenem alone and in
combination with dipicolinic acid, aminophenylboronic acid, and
cloxacillin, with a disk of temocillin for screening OXA-48-
producing strains.3,4
The comparison of the MICs determined with the
different methods was performed using the Student’s
exact test or the non-parametric Kruskal–Wallis test, as
appropriate.
Table 2
Ertapenem MICs (mg/ml) according to three different methods: comparison
between Enterobacter cloacae producing ESBL and not
MIC Production of an ESBL Absence of ESBL
Vitek 2 2.8  1.6 3.1  1.9
Etest strips 0.91  0.88 0.97  0.82
Dilution in agar medium 0.89  0.63 0.97  0.62
MIC, minimal inhibitory concentration; ESBL, extended-spectrum beta-lactamase.
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Fifty E. cloacae with a MIC of ertapenem >0.5 mg/ml determined
by Vitek 2 system were isolated from 50 patients hospitalized on
20 different wards of the hospital. These isolates were from clinical
or screening samples. An ESBL was identiﬁed in 52% of the strains.
No carbapenemase was detected by the screening method used.
The mean MIC of ertapenem was 2.92  1.77 mg/ml according to
the Vitek 2 system, 0.94  0.84 mg/ml according to the Etests, and
0.93  0.62 mg/ml according to the APDM. The mean MIC determined
by Vitek 2 system was signiﬁcantly different to those determined by
Etest strips and APDM (p < 0.02 and p < 0.05, respectively). Further-
more, the MICs determined by the Vitek 2 system were higher than
the MICs determined by the two other methods for 96% of strains
(Table 1). The mean ratio MIC Vitek 2 system/MIC Etest and MIC Vitek
2 system/MIC APDM was 5.2. The differences between the MICs were
similar for ESBL-producing and ESBL-non-producing strains (Table 2).
Lastly, according to the Etest strips and APDM, 42% of E. cloacae were
susceptible to ertapenem (no strain was susceptible according to the
Vitek 2 system). The mean MICs were 0.38 mg/ml for imipenem,
0.13 mg/ml for meropenem, and 0.11 mg/ml for doripenem.
Ertapenem has been described as the most appropriate
carbapenem for detecting carbapenemase producers, especially
those with low-level resistance to carbapenems.4–6 In our
experience, no E. cloacae identiﬁed as being intermediate or
resistant to ertapenem with the Vitek 2 system has been a
carbapenemase producer. The proportion of non-susceptible
strains identiﬁed in the same population by the two other methods
was only 58%. Therefore it appears that using the Vitek 2 system
may lead to some excessive additional tests, such as the
determination of MICs for other carbapenems and carbapene-
mase-detecting tests for third-generation cephalosporin-resistant
E. cloacae strains. Moreover, the possibly falsely diagnosed non-
susceptible strains may lead to an excessive use of other
carbapenems that have a broader antimicrobial spectrum.
However, two considerations must be taken into account for the
interpretation of these results. First, carbapenemase production is
not the only mechanism that confers a reduced susceptibility to
certain carbapenems. In addition, the inoculum effect can play a
major role in the determination of the MIC.Finally, it is noticeable that the ertapenem MIC of the OXA-48-
producing K. pneumoniae that was used as a control in our study
was measured as 4 mg/ml (resistant) with the Vitek 2 system, and
as 0.50 mg/ml (susceptible) by Etest. Therefore, it would be
interesting to determine if the Vitek 2 system is more effective for
the detection of carbapenemase producers with low-level carba-
penem resistance than the two methods performed in agar
medium.
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